Summary
Global Markets Direct’s, ‘Heptares Therapeutics Limited - Product Pipeline Review - 2016’, provides an overview of the Heptares Therapeutics Limited’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Heptares Therapeutics Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Heptares Therapeutics Limited
- The report provides overview of Heptares Therapeutics Limited including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Heptares Therapeutics Limited’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Heptares Therapeutics Limited’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Heptares Therapeutics Limited’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Heptares Therapeutics Limited
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Heptares Therapeutics Limited’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Heptares Therapeutics Limited Snapshot 6
Heptares Therapeutics Limited Overview 6
Key Information 6
Key Facts 6
Heptares Therapeutics Limited - Research and Development Overview 7
Key Therapeutic Areas 7
Heptares Therapeutics Limited - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Out-Licensed Products 12
Out-Licensed Products/Combination Treatment Modalities 13
Heptares Therapeutics Limited - Pipeline Products Glance 14
Heptares Therapeutics Limited - Clinical Stage Pipeline Products 14
Phase I Products/Combination Treatment Modalities 14
Heptares Therapeutics Limited - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Heptares Therapeutics Limited - Drug Profiles 17
HTL-9936 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Drug to Agonize Muscarinic M1 and M4 Receptors for Psychosis and Neurologic Diseases 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Drug to Agonize Muscarinic M4 Receptors for Psychiatric Diseases and Alzheimer's Disease 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
HTL-1071 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
HTL-14242 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
HTL-6641 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Small Molecule to Agonize GLP-1 Receptor for Type 2 Diabetes 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Small Molecule to Agonize GPR39 for Type 1 and Type 2 Diabetes 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Monoclonal Antibody to Antagonize GPCR for Inflammation 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Monoclonal Antibody to Target GPCR for Undisclosed Indications 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Small Molecule to Antagonize CXCR4 for Cancer and HIV 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecule to Antagonize GLP-1 Receptor Hypoglycemia 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecule to Target GPCR for CNS Disorders 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Small Molecule to Target mGluR2 for Schizophrenia 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Small Molecules to Target GPCR for Pain, Cardiovascular, Metabolic and Inflammatory Disorders 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Heptares Therapeutics Limited - Pipeline Analysis 33
Heptares Therapeutics Limited - Pipeline Products by Target 33
Heptares Therapeutics Limited - Pipeline Products by Route of Administration 34
Heptares Therapeutics Limited - Pipeline Products by Molecule Type 35
Heptares Therapeutics Limited - Pipeline Products by Mechanism of Action 36
Heptares Therapeutics Limited - Recent Pipeline Updates 37
Heptares Therapeutics Limited - Dormant Projects 42
Heptares Therapeutics Limited - Locations And Subsidiaries 43
Head Office 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 44
Disclaimer 45
List of Tables
Heptares Therapeutics Limited, Key Information 6
Heptares Therapeutics Limited, Key Facts 6
Heptares Therapeutics Limited - Pipeline by Indication, 2016 8
Heptares Therapeutics Limited - Pipeline by Stage of Development, 2016 10
Heptares Therapeutics Limited - Monotherapy Products in Pipeline, 2016 11
Heptares Therapeutics Limited - Out-Licensed Products in Pipeline, 2016 12
Heptares Therapeutics Limited - Out-Licensed Products/ Combination Treatment Modalities, 2016 13
Heptares Therapeutics Limited - Phase I, 2016 14
Heptares Therapeutics Limited - Preclinical, 2016 15
Heptares Therapeutics Limited - Discovery, 2016 16
Heptares Therapeutics Limited - Pipeline by Target, 2016 33
Heptares Therapeutics Limited - Pipeline by Route of Administration, 2016 34
Heptares Therapeutics Limited - Pipeline by Molecule Type, 2016 35
Heptares Therapeutics Limited - Pipeline Products by Mechanism of Action, 2016 36
Heptares Therapeutics Limited - Recent Pipeline Updates, 2016 37
Heptares Therapeutics Limited - Dormant Developmental Projects,2016 42
List of Figures
Heptares Therapeutics Limited - Pipeline by Top 10 Indication, 2016 8
Heptares Therapeutics Limited - Pipeline by Stage of Development, 2016 10
Heptares Therapeutics Limited - Monotherapy Products in Pipeline, 2016 11
Heptares Therapeutics Limited - Out-Licensed Products in Pipeline, 2016 12
Heptares Therapeutics Limited - Pipeline by Top 10 Target, 2016 33
Heptares Therapeutics Limited - Pipeline by Route of Administration, 2016 34
Heptares Therapeutics Limited - Pipeline by Molecule Type, 2016 35
Heptares Therapeutics Limited - Pipeline Products by Top 10 Mechanism of Action, 2016 36
